{"retracted":false,"update":{"timestamp":1191283200000,"doi":"10.1073/pnas.0708144104","type":"correction"},"doi":"10.1073/pnas.0611693104","journal":"Proceedings of the National Academy of Sciences","publisher":"Proceedings of the National Academy of Sciences","title":"Correction for Scott et al., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors"}
